Recurrent head and neck tumors have gene mutations that could be vulnerable to cancer drug

An examination of the genetic landscape of head and neck cancers indicates that while metastatic and primary tumor cells share similar mutations, recurrent disease is associated with gene alterations that could be exquisitely sensitive to an existing cancer drug.